research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
Search
for
Sort by
Research
540-570 / 1000+ results research BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Efficacy and Safety of Topical Corticosteroid Treatment under Occlusion for Severe Alopecia Areata in Children. A single-center retrospective analysis
Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.
research Is thyroid dysfunction a common cause of telogen effluvium?: A retrospective study
Hypothyroidism is often linked to the hair loss condition telogen effluvium.
research Growth Factors and Microneedling in Alopecia Areata: A Narrative Review
Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.
research Two‐dimensional planimetry for alopecia areata severity evaluation compared with severity of alopecia tool: A pilot study
Measuring bald patch size can help grade hair loss severity, with photograph-based evaluation being more reliable.
research Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Diagnosis and severity assessment
There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.
research Alopesia universalis pada anak yang berespon baik dengan terapi kombinasi: sebuah laporan kasus
A young child with complete hair loss improved significantly with a combination of hair growth treatments and laser therapy.
research 701 Rethinking alopecia scores: Correlating measures of hair loss with established photographic scoring systems
The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research Retrospective Analysis of Pediatric Alopecia Areata Treated with Methotrexate
Methotrexate may effectively and safely treat hair loss in children, with notable improvement after 12-15 months.
research A randomised, open label comparative study of hydroxychloroquine with betamethasone oral mini pulse in the management of patients with alopecia areata
Hydroxychloroquine is less effective than betamethasone oral mini pulse therapy for treating alopecia areata.
research Successful Treatment of Alopecia Totalis with Topical Calcipotriol: Serial Case Report and Review of the Literature
Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.
research 1315 An Integrated model of alopecia areata biomarkers highlights both Th1/Th2 upregulation, with stronger correlations between Th2 activation and disease severity
Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.
research Investigating the mechanisms underlying effects of testosterone on blood pressure in normotensive and hypertensive rats / Loh Su Yi
Testosterone raises blood pressure by affecting kidney function and brain gene regulation over time.
research Study of the base influence on the foaming properties gel shampoo with minoxidil
Anionic surfactants significantly improve the foaming of minoxidil gel shampoo.
research Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Case Report: Dupilumab induced sustained complete remission in a child with severe alopecia areata and markedly elevated IgE
Dupilumab effectively treated severe alopecia areata in a child.
research Limitations of Treatment-Induced Alopecia Grading Instruments in Evaluating Therapeutic Response
This study evaluates the effectiveness of the Dean Scale compared to the CTCAE scale in assessing therapeutic response to minoxidil in patients with anticancer therapy-induced alopecia. The Dean Scale showed better diagnostic accuracy with an area under the ROC curve of 0.74, compared to 0.55 for the CTCAE scale, indicating the latter's ineffectiveness in detecting changes in hair density. However, the Dean Scale failed to capture regrowth in 45.8% of patients with moderate-to-significant clinical response. The study concludes that current classification methods, like the CTCAE, may not accurately capture clinically significant hair regrowth, suggesting the need for adopting the SALT II severity classification and incorporating objective trichoscopic evaluations for better tracking of treatment-related alopecia.
research Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
research AYURVEDIC MANAGEMENT OF ALOPECIA AREATA USING VIDDHAKARMA AS A PARA-SURGICAL PROCEDURE: A CASE STUDY
Viddhakarma may effectively regrow hair in alopecia areata without side effects.
research Advancing Hair Loss Assessment in Alopecia Areata: The Mathematical Case for Centralised, Standardised Imaging
Centralized imaging provides more accurate and consistent hair loss measurements in alopecia areata.
research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
STS01 1% effectively promotes hair regrowth with minimal side effects.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.